MPM BioImpact’s Black Diamond Therapeutics BDTX Stock Holding History

MPM BioImpact’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-144,888	Closed	-$274K	–	36
2023 Q1	$274K	Hold	144,888	–	–	0.07%	31
2022 Q4	$261K	Sell	144,888 -95,000	-40%	-$171K	0.07%	32
2022 Q3	$405K	Hold	239,888	–	–	0.1%	38
2022 Q2	$590K	Hold	239,888	–	–	0.16%	37
2022 Q1	$664K	Hold	239,888	–	–	0.18%	37
2021 Q4	$1.28M	Sell	239,888 -8,618	-3%	-$60.2K	0.23%	33
2021 Q3	$2.1M	Buy	+248,506	New	+$2.45M	0.33%	33

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact's BDTX Position: Q2 2023 in Review

MPM BioImpact sold out of Black Diamond Therapeutics (BDTX) in Q2 2023, closing a stake of 144,888 shares — an estimated $274K sold.

MPM BioImpact first reported a position in BDTX in Q3 2021 and held it in 7 quarters. The position peaked at $2.1M in Q3 2021. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2023.

MPM BioImpact reported no remaining Black Diamond Therapeutics position as of Q2 2023 after selling out during the quarter.
MPM BioImpact sold 144,888 Black Diamond Therapeutics shares in Q2 2023, an estimated $274K.
MPM BioImpact first reported a position in Black Diamond Therapeutics in Q3 2021 and held it in 7 quarters.
MPM BioImpact's Black Diamond Therapeutics position peaked at $2.1M in Q3 2021.
74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2023.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.